<aside> đź’ˇ Bingo Card:
If you’d told me in 2017 that launching a plant-based therapeutics company would require me to become an amateur trademark attorney, a regulatory detective, a shelf-stability scientist, and—at times—a crisis negotiator, I would have asked for a different Bingo card. Yet here I am, having navigated more plot twists than I ever imagined when Faeve first started as my “fun side project” after school.
Along the way, I’ve fielded cease-and-desist letters from industry giants, untangled surprise IRS filings, learned more about federal regulations than I ever wanted, and personally funded every “unexpected” milestone—usually with a healthy dose of disbelief and humor. I’ve pivoted from kitchen experiments to mid-scale manufacturing, survived the OTC regulatory gauntlet, and discovered that plants aren’t the only things that need to be resilient in this business.
Despite all these unexpected detours, Faeve has not only survived but is now poised for real, scalable growth. What you’re investing in isn’t just a company with strong margins and a loyal customer base—it’s a founder who’s made it through every “not on the Bingo card” moment, and is more committed than ever to taking this brand to the next level.
</aside>